Palisade Bio, Inc.
PALIPalisade Bio, Inc. in brief
Palisade Bio, Inc. is a listed company in the Biotechnology industry, based in Maryland, USA. Its market value was $215 M on 28 October 2026, which makes it the 15,982nd largest listed company in the world and the 3,111th largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $17 M. It employs about 14 people and J.D. Finley is its chief executive. Its shares trade under the symbol PALI (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Palisade Bio, Inc.
We are a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon. Our lead clinical product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
We are committed to advancing a next generation of once daily, oral PDE4 inhibitor prodrugs to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases.
We are developing a biomarker-based patient selection approach that we believe may aid clinicians in identifying patients who may better respond to PALI-2108, thereby improving the rate of clinical response previously demonstrated with PDE4 inhibitors. Our approach involves the use of clinical and multiomics data from large patient populations to identify PDE4-related biomarkers that are correlated with IBD, its severity, and which are modified with local PDE4-inhibitor therapy in the colon. Based on our research, we have initiated the development of corresponding biomarker assays for these PDE4-related biomarkers that we expect to use in our current and future clinical studies with the aim of developing regulatory approved tests for selecting potential responders to PALI-2108.
From the company's annual report filed with the US SEC: read the report
Palisade Bio, Inc. timeline
- 2006
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2020
- ✎Renamed Seneca Biopharma, Inc.Formerly Neuralstem, Inc..
- 2021
- ✎Renamed Palisade Bio, Inc.Formerly Seneca Biopharma, Inc..
Events of Palisade Bio, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #5,441 (Jan 2022) · #5,847 (Dec 2022) · #5,293 (Jul 2023) · #4,630 (Jan 2024) · #1,617 (Mar 2026) · #2,718 (Aug 2026) · #2,972 (Oct 2026) · #3,115 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 1.7×
- Free cash flow yield
- -5.7%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -13.0%
- Liabilities / assets
- 3.7%
- Net debt
- $-10M
- Revenue growth
- +2400.0%
- R&D / revenue
- 2756.0%
- Revenue per employee
- $0 K
- Profit per employee
- $-1.2 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-18M | $-17M | — |
| Dec 2024 | — | — | $-15M | $-14M | — |
| Dec 2023 | $0M | — | $-13M | $-12M | -4920.0% |
| Dec 2022 | — | — | $-16M | $-14M | — |
| Dec 2021 | — | — | $-42M | $-27M | — |
| Dec 2020 | $0M | -50.0% | $-9M | $-10M | -103200.0% |
| Dec 2019 | $0M | -92.3% | $-9M | $-8M | -41750.0% |
| Dec 2018 | $0M | — | $-8M | $-5M | -1892.3% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-11M | — | — | $-0.30 | — |
| Dec 2024 | $-12M | $0M | $-12M | $-10.19 | — |
| Dec 2023 | $-11M | $0M | $-11M | $-27.01 | — |
| Dec 2022 | $-13M | $0M | $-13M | $-16.53 | — |
| Dec 2021 | $-15M | $0M | $-15M | $-169.74 | — |
| Dec 2020 | $-5M | $0M | $-5M | $-3.72 | — |
| Dec 2019 | $-7M | — | — | $-3.80 | — |
| Dec 2018 | $-8M | $0M | $-8M | $-7.54 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-15M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 20268-KCurrent reportResults of operations
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Aug 10, 20268-KCurrent reportResults of operations
- Aug 10, 202610-QQuarterly report · period to Jun 2026
- Jun 11, 20268-KCurrent reportDirectors or officers changed · Bylaws amended · Shareholder vote
- May 12, 20268-KCurrent reportResults of operations
- May 12, 202610-QQuarterly report · period to Mar 2026
- Apr 29, 2026DEF 14AProxy statement
- Apr 2, 20268-KCurrent reportOther events
- Mar 20, 202610-KAnnual report · period to Dec 2025
- Dec 4, 20258-KCurrent reportBylaws amended · Shareholder vote
- Nov 10, 202510-QQuarterly report · period to Sep 2025
Official filings of Palisade Bio, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $0 M
- Operating income
- $-18 M
- Net income
- $-17 M
For year ending December-2025
Balance sheet
- Total assets
- $134 M
- Total liabilities
- $5 M
- Total equity
- $129 M
As of December-2025
Top 100 institutional investors in Palisade Bio, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Soleus Capital Management, L.P. | 14,996,154 | +1,932,467 (+14.79%) | 8.36% | $20 M | Nov 16, 2026 |
| 2 | Ameriprise Financial Inc | 14,567,993 | +3,486,559 (+31.46%) | 8.13% | $20 M | Nov 16, 2026 |
| 3 | B Group, Inc. | 11,414,285 | 0 (0.00%) | 6.37% | $15 M | Nov 16, 2026 |
| 4 | BlackRock, Inc. | 11,095,890 | +659,130 (+6.32%) | 6.19% | $15 M | Nov 13, 2026 |
| 5 | Janus Henderson Group Ltd. | 10,689,452 | — | 5.96% | $14 M | Nov 16, 2026 |
| 6 | Octagon Capital Advisors LP | 10,276,317 | 0 (0.00%) | 5.73% | $14 M | Nov 16, 2026 |
| 7 | Perceptive Advisors LLC | 8,425,065 | 0 (0.00%) | 4.70% | $11 M | Nov 16, 2026 |
| 8 | Vanguard Capital Management LLC | 7,888,020 | +6,165,203 (+357.86%) | 4.40% | $11 M | Nov 13, 2026 |
| 9 | Ra Capital Management, L.P. | 7,124,116 | 0 (0.00%) | 3.97% | $10 M | Nov 16, 2026 |
| 10 | Franklin Templeton Inc | 6,069,746 | +284,557 (+4.92%) | 3.39% | $8 M | Nov 12, 2026 |
| 11 | Point72 Asset Management, L.P. | 5,873,267 | +619,864 (+11.80%) | 3.28% | $8 M | Nov 16, 2026 |
| 12 | Wellington Management Group LLP | 5,410,568 | +1,706,632 (+46.08%) | 3.02% | $7 M | Nov 16, 2026 |
| 13 | Boxer Capital Management, LLC | 4,799,875 | 0 (0.00%) | 2.68% | $6 M | Nov 16, 2026 |
| 14 | Adage Capital Partners GP, L.L.C. | 4,500,000 | 0 (0.00%) | 2.51% | $6 M | Nov 16, 2026 |
| 15 | Geode Capital Management, LLC | 3,858,682 | +98,197 (+2.61%) | 2.15% | $5 M | Nov 6, 2026 |
| 16 | Eversept Partners, LP | 3,474,548 | -708,237 (-16.93%) | 1.94% | $5 M | Nov 16, 2026 |
| 17 | Federated Hermes, Inc. | 3,136,607 | 0 (0.00%) | 1.75% | $4 M | Nov 12, 2026 |
| 18 | Squadron Capital Management LLC | 3,000,000 | 0 (0.00%) | 1.67% | $4 M | Nov 16, 2026 |
| 19 | State Street Corp | 2,933,459 | +457,811 (+18.49%) | 1.64% | $4 M | Nov 12, 2026 |
| 20 | Goldman Sachs Group Inc | 2,719,130 | -858,890 (-24.00%) | 1.52% | $4 M | Nov 16, 2026 |
| 21 | Vestal Point Capital, LP | 2,500,000 | 0 (0.00%) | 1.39% | $3 M | Nov 16, 2026 |
| 22 | Sphera Funds Management LTD. | 2,464,038 | +206,932 (+9.17%) | 1.37% | $3 M | Nov 16, 2026 |
| 23 | Silverarc Capital Management, LLC | 2,335,602 | New | 1.30% | $3 M | Nov 12, 2026 |
| 24 | Aberdeen Group plc | 2,276,844 | +366,639 (+19.19%) | 1.27% | $3 M | Nov 10, 2026 |
| 25 | Propel Bio Management, LLC | 2,224,189 | -358,199 (-13.87%) | 1.24% | $3 M | Nov 13, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Platinum Investment Management LTD | 2,184,388 | +453,522 (+26.20%) | 1.22% | $3 M | Nov 16, 2026 |
| 27 | Los Angeles Capital Management LLC | 2,130,631 | +2,072,246 (+3549.28%) | 1.19% | $3 M | Nov 12, 2026 |
| 28 | Siren, L.L.C. | 2,000,000 | 0 (0.00%) | 1.12% | $3 M | Nov 12, 2026 |
| 29 | ADAR1 Capital Management, LLC | 1,541,747 | -184,915 (-10.71%) | 0.86% | $2 M | Nov 16, 2026 |
| 30 | Vanguard Portfolio Management LLC | 1,442,126 | +448,031 (+45.07%) | 0.80% | $2 M | Nov 13, 2026 |
| 31 | Northern Trust Corp | 1,250,733 | +53,113 (+4.43%) | 0.70% | $2 M | Nov 16, 2026 |
| 32 | HighVista Strategies LLC | 1,151,082 | -879,845 (-43.32%) | 0.64% | $2 M | Nov 13, 2026 |
| 33 | Vanguard Fiduciary Trust Co | 1,117,461 | +231,549 (+26.14%) | 0.62% | $2 M | Nov 13, 2026 |
| 34 | UBS Group AG | 1,078,227 | +340,920 (+46.24%) | 0.60% | $1 M | Nov 10, 2026 |
| 35 | Millennium Management LLC | 917,062 | -17,093 (-1.83%) | 0.51% | $1 M | Nov 16, 2026 |
| 36 | Creek Drive Management Group LLC | 680,000 | +240,000 (+54.55%) | 0.38% | $1 M | Nov 10, 2026 |
| 37 | BIT Capital GmbH | 679,000 | +105,000 (+18.29%) | 0.38% | $1 M | Nov 13, 2026 |
| 38 | Nuveen, LLC | 524,637 | -444,820 (-45.88%) | 0.29% | $1 M | Nov 10, 2026 |
| 39 | Atom Investors LP | 516,922 | New | 0.29% | $1 M | Nov 16, 2026 |
| 40 | Charles Schwab Investment Management Inc | 456,845 | +21,862 (+5.03%) | 0.25% | $1 M | Nov 16, 2026 |
| 41 | Simplify Asset Management Inc. | 434,333 | -16,210 (-3.60%) | 0.24% | $1 M | Oct 27, 2026 |
| 42 | Susquehanna International Group, LLP | 426,747 | +395,842 (+1280.83%) | 0.24% | $1 M | Nov 16, 2026 |
| 43 | Ikarian Capital, LLC | 400,000 | -350,000 (-46.67%) | 0.22% | $1 M | Nov 16, 2026 |
| 44 | Bank of New York Mellon Corp | 368,417 | +19,948 (+5.72%) | 0.21% | $0 M | Nov 5, 2026 |
| 45 | Balyasny Asset Management L.P. | 357,914 | -1,517,780 (-80.92%) | 0.20% | $0 M | Nov 16, 2026 |
| 46 | XTX Topco Ltd | 346,581 | +216,318 (+166.06%) | 0.19% | $0 M | Nov 16, 2026 |
| 47 | Boothbay Fund Management, LLC | 324,022 | -113,115 (-25.88%) | 0.18% | $0 M | Nov 16, 2026 |
| 48 | ACT Capital Partners, L.P. | 307,500 | — | 0.17% | $0 M | Nov 6, 2026 |
| 49 | Voleon Capital Management LP | 274,348 | +255,501 (+1355.66%) | 0.15% | $0 M | Nov 16, 2026 |
| 50 | Seven Fleet Capital Management LP | 272,204 | 0 (0.00%) | 0.15% | $0 M | Nov 16, 2026 |
| 51 | American Century Companies Inc | 205,883 | +81,192 (+65.11%) | 0.11% | $0 M | Nov 12, 2026 |
| 52 | Rhumbline Advisers | 172,442 | +11,669 (+7.26%) | 0.10% | $0 M | Nov 10, 2026 |
| 53 | Persistent Asset Partners Ltd | 138,953 | +97,489 (+235.12%) | 0.08% | $0 M | Nov 13, 2026 |
| 54 | Bank Of America Corp /de/ | 131,682 | -42,179 (-24.26%) | 0.07% | $0 M | Nov 16, 2026 |
| 55 | Deutsche Bank AG\ | 125,924 | -18,076 (-12.55%) | 0.07% | $0 M | Nov 6, 2026 |
| 56 | Price T Rowe Associates Inc /MD/ | 121,152 | 0 (0.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 57 | Morgan Stanley | 115,433 | -2,358,636 (-95.33%) | 0.06% | $0 M | Nov 13, 2026 |
| 58 | Pale Fire Capital SE | 111,410 | 0 (0.00%) | 0.06% | $0 M | Nov 13, 2026 |
| 59 | Creative Planning | 91,474 | New | 0.05% | $0 M | Nov 2, 2026 |
| 60 | LPL Financial LLC | 88,004 | -54,150 (-38.09%) | 0.05% | $0 M | Nov 6, 2026 |
| 61 | Sectoral Asset Management Inc | 88,000 | 0 (0.00%) | 0.05% | $0 M | Nov 13, 2026 |
| 62 | China Universal Asset Management Co., Ltd. | 81,000 | +13,110 (+19.31%) | 0.05% | $0 M | Oct 28, 2026 |
| 63 | Jpmorgan Chase & Co | 78,303 | +13,588 (+21.00%) | 0.04% | $0 M | Nov 12, 2026 |
| 64 | Invesco Ltd. | 72,499 | -4,899 (-6.33%) | 0.04% | $0 M | Nov 12, 2026 |
| 65 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 71,331 | +3,657 (+5.40%) | 0.04% | $0 M | Nov 16, 2026 |
| 66 | Diadema Partners LP | 69,533 | New | 0.04% | $0 M | Nov 16, 2026 |
| 67 | Vanguard Global Advisers, LLC | 67,615 | +15,323 (+29.30%) | 0.04% | $0 M | Nov 13, 2026 |
| 68 | MetLife Investment Management, LLC | 66,015 | -21,860 (-24.88%) | 0.04% | $0 M | Nov 16, 2026 |
| 69 | Barclays PLC | 58,743 | +22,490 (+62.04%) | 0.03% | $0 M | Nov 6, 2026 |
| 70 | Alliancebernstein L.P. | 52,040 | 0 (0.00%) | 0.03% | $0 M | Nov 16, 2026 |
| 71 | Police & Firemen's Retirement System of New Jersey | 43,530 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 72 | Manufacturers Life Insurance Company, The | 41,554 | +1,422 (+3.54%) | 0.02% | $0 M | Nov 13, 2026 |
| 73 | PCG Wealth Advisors, LLC | 41,100 | 0 (0.00%) | 0.02% | $0 M | Nov 10, 2026 |
| 74 | BNP Paribas Financial Markets | 37,407 | +14,857 (+65.88%) | 0.02% | $0 M | Nov 12, 2026 |
| 75 | New York State Common Retirement Fund | 33,100 | 0 (0.00%) | 0.02% | $0 M | Nov 17, 2026 |
| 76 | Wells Fargo & Company/mn | 32,731 | -92,836 (-73.93%) | 0.02% | $0 M | Nov 16, 2026 |
| 77 | Voya Investment Management LLC | 29,672 | +1,529 (+5.43%) | 0.02% | $0 M | Nov 10, 2026 |
| 78 | Panagora Asset Management Inc | 24,143 | New | 0.01% | $0 M | Nov 12, 2026 |
| 79 | AQR Capital Management LLC | 23,881 | New | 0.01% | $0 M | Nov 16, 2026 |
| 80 | Prudential Financial Inc | 22,265 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 81 | NFSG Corp | 20,250 | 0 (0.00%) | 0.01% | $0 M | Oct 15, 2026 |
| 82 | PFG Investments, LLC | 20,000 | New | 0.01% | $0 M | Nov 12, 2026 |
| 83 | ProShare Advisors LLC | 19,213 | -112 (-0.58%) | 0.01% | $0 M | Oct 29, 2026 |
| 84 | Victory Capital Management Inc | 18,792 | -965 (-4.88%) | 0.01% | $0 M | Nov 10, 2026 |
| 85 | Royal Bank Of Canada | 18,185 | +13,617 (+298.10%) | 0.01% | $0 M | Nov 16, 2026 |
| 86 | Landscape Capital Management, L.L.C. | 17,922 | -418,804 (-95.90%) | 0.01% | $0 M | Nov 10, 2026 |
| 87 | Wealth Enhancement Advisory Services, LLC | 17,235 | -11,993 (-41.03%) | 0.01% | $0 M | Oct 13, 2026 |
| 88 | CIBC Bancorp USA Inc. | 17,128 | +6,980 (+68.78%) | 0.01% | $0 M | Nov 13, 2026 |
| 89 | Choreo, LLC | 15,743 | 0 (0.00%) | 0.01% | $0 M | Oct 28, 2026 |
| 90 | Squarepoint Ops LLC | 14,636 | -71,342 (-82.98%) | 0.01% | $0 M | Nov 9, 2026 |
| 91 | Legal & General Group Plc | 14,323 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 92 | WINTON GROUP Ltd | 14,300 | -17,927 (-55.63%) | 0.01% | $0 M | Nov 12, 2026 |
| 93 | Xponance LLC | 13,822 | -244 (-1.73%) | 0.01% | $0 M | Nov 3, 2026 |
| 94 | Ameritas Investment Partners, Inc. | 13,395 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 95 | Kestra Advisory Services, LLC | 12,504 | 0 (0.00%) | 0.01% | $0 M | Nov 2, 2026 |
| 96 | Russell Investments Group, Ltd. | 11,770 | 0 (0.00%) | 0.01% | $0 M | Nov 6, 2026 |
| 97 | Public Employees Retirement System Of Ohio | 11,737 | New | 0.01% | $0 M | Nov 16, 2026 |
| 98 | Global Retirement Partners, LLC | 10,389 | New | 0.01% | $0 M | Nov 10, 2026 |
| 99 | Osaic Holdings, Inc. | 10,066 | +10,000 (+15151.52%) | 0.01% | $0 M | Nov 12, 2026 |
| 100 | SBI Securities Co., Ltd. | 10,000 | New | 0.01% | $0 M | Oct 22, 2026 |
Mutual funds holding Palisade Bio, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 3.73 M | $8 M | 2.1% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Federated Hermes Kaufmann Small Cap FundFederated Advisory Services Company | 3.14 M | $6 M | 1.7% | 0.21% | no change | Jul 31, 2026 |
| 🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc. | 2.12 M | $4 M | 1.2% | 0.35% | no change | Jul 31, 2026 |
| 🇺🇸 abrdn Life Sciences Investorsabrdn Inc. | 1.91 M | $4 M | 1.1% | 0.58% | +188% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 1.72 M | $4 M | 0.96% | <0.01% | +21% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 1.61 M | $3 M | 0.90% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 1.12 M | $2 M | 0.62% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 773,196 | $1 M | 0.43% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 667,004 | $1 M | 0.37% | <0.01% | −1.6% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 495,848 | $1 M | 0.28% | 0.07% | new | Jun 30, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 380,673 | $1 M | 0.21% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 358,983 | $1 M | 0.20% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 275,899 | $1 M | 0.15% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 269,212 | $1 M | 0.15% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 246,405 | $1 M | 0.14% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 196,088 | $0 M | 0.11% | <0.01% | −15% | May 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 196,261 | $0 M | 0.11% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 169,895 | $0 M | 0.09% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 159,559 | $0 M | 0.09% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 108,700 | $0 M | 0.06% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 99,684 | $0 M | 0.06% | <0.01% | +11% | May 31, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 101,600 | $0 M | 0.06% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC | 84,945 | $0 M | 0.05% | 0.01% | +3.9% | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 80,446 | $0 M | 0.04% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 76,393 | $0 M | 0.04% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 76,000 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 70,212 | $0 M | 0.04% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 49,821 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 47,400 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS | 45,286 | $0 M | 0.03% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P. | 43,055 | $0 M | 0.02% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 42,319 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 33,326 | $0 M | 0.02% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 32,829 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 32,756 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Multi-Manager U.S. Small Cap Equity FundGoldman Sachs Asset Management, L.P. | 32,796 | $0 M | 0.02% | 0.02% | — | Apr 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 30,635 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 26,020 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 26,020 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 24,895 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 25,851 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 23,150 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 22,254 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 19,964 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 18,775 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 19,757 | $0 M | 0.01% | <0.01% | +20% | Jul 31, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 17,869 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 17,284 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 13,395 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 13,052 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 11,770 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 10,274 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 9,090 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 9,875 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 8,255 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 6,653 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 5,184 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 5,164 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 3,882 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 3,726 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 2,692 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 2,340 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 2,009 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 63 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Palisade Bio, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Julien E. CapersSee Remarks | Grant or award | +787,300 | — | — | 787,300 | Form 4 |
| filed | Mitchell Lawrence JonesSee Remarks | Option exercise | +2.62 M | — | — | 2.71 M | Form 4 |
| filed | John David FinleyCEO CFO, Director | Option exercise | +3.23 M | — | — | 3.36 M | Form 4 |
| filed | Mitchell Lawrence JonesSee Remarks | Shares withheld for tax | -1.03 M | $1.490 | $1.5 M | 1.68 M | Form 4 |
| filed | John David FinleyCEO CFO, Director | Shares withheld for tax | -1.41 M | $1.490 | $2.1 M | 1.94 M | Form 4 |
| filed | Donald Allen WilliamsDirector | Buy | +10,000 | $1.460 | $15 K | 1.59 M | Form 4 |
| filed | Donald Allen WilliamsDirector | Buy | +10,000 | $1.420 | $14 K | 1.58 M | Form 4 |
| filed | John David FinleyCEO, CFO, Director | Gift | -88,400 | — | — | 129,288 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Palisade Bio, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2024-12-12 17:05 UTC, code LUDP, resumed 17:10 UTC
Fails to deliver
- : 12,907 shares at $1.20
- : 97,283 shares at $1.23
- : 4,140 shares at $1.41
- : 6,017 shares at $1.54
- : 14,204 shares at $1.47
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Palisade Bio, Inc. scorecard#
Passes 2 of the 11 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 28, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.7×Price to book 1.7× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-5.7%Free cash flow is -5.7% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.30 vs -10.19Diluted EPS -0.30 in fiscal 2025 against -10.19 the year before (report's currency).
- ✗Net income higher than five years earlier-$17 M-$17 M in fiscal 2025 against -$10 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$17 MNet income -$17 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-24.5%-24.5% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities28.9×Current ratio 28.93 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Palisade Bio, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0—— | 0−100%— | 0.3—100% | 0—— | — | 0.0−12.2%100% | 0.0−94.1%100% | 0.30.0%100% | 0.3+1500%100% | 0.0—100% | |
| Research and development | 10−36.3%— | 16r9.1+132%— | 6.9+5.3%2757% | 6.5+169%— | 2.4+20.4%— | 2.0−50.3%14929% | 4.1+2.6%26383% | 4.0−51.1%1523% | 8.1−38.5%3114% | 13—80979% | |
| General and administrative | 7.9+35.7%— | 5.8−6.5%— | 6.2−29.2%2481% | 8.8−5.8%— | 9.3+50.2%— | 6.2r8.7+35.2%45843% | 4.6+0.6%29788% | 4.6−16.7%1754% | 5.5−27.0%2104% | 7.5—46148% | |
| Operating expenses | 18+21.5%— | 15+11.6%— | 13−15.3%5328% | 16−62.4%— | 42+350%— | 9.3r11+7.5%68765% | 8.6+1.5%56172% | 8.5−37.2%3277% | 14−34.3%5218% | 21—127127% | |
| Operating income | −18—— | −15—— | −13—−5228% | −16—— | −42—— | −9.3r−11—−68765% | −8.6—−56072% | −8.3—−3177% | −13—−5118% | −21—−127027% | |
| Interest and finance income | — | — | — | — | — | 0.0−50.5%248% | 0.1−14.0%440% | 0.1+12.1%30.3% | 0.1+19.4%27.0% | 0.1—362% | |
| Interest expense and finance costs | 0.0−16.7%— | 0.0−20.0%— | 0.0+15.4%6.0% | 0.0−99.5%— | 2.4+920%— | 0.2r0.0+2535%1738% | 0.0+15.9%57.9% | 0.0−95.2%3.0% | 0.2−86.1%61.2% | 1.1—7025% | |
| Other non-operating income (expense) | 1.3+203%— | 0.4−45.3%— | 0.8−47.3%308% | 1.5−90.4%— | 15—— | −1.0r−5.6−466%−7581% | 0.3−91.6%1819% | 3.3—1283% | −2.4—−907% | −0.4—−2695% | |
| Income tax | 0—— | 0—— | 0—0.0% | 0—— | 0−100%— | 0.0—7.4% | — | — | — | 0—0.0% | |
| Net income attributable to shareholders | −17—— | −14—— | −12—−4920% | −14—— | −27—— | −10r−16—−76346% | −8.4—−54253% | −4.9—−1894% | −16—−6025% | −21—−129722% | |
| Earnings per share, basic | -0.30—— | -10.19—— | -27.01r-1.80—— | -16.53—— | -142.95r-2.86—— | -3.72r-1.17—— | -3.80—— | -7.54r-0.32—— | -1.20—— | -2.53—— | |
| Earnings per share, diluted | -0.30—— | -10.19—— | -27.01r-1.80—— | -16.53—— | -169.74r-3.39—— | -3.72r-1.17—— | -3.80—— | -7.54r-0.32—— | -1.20—— | -2.53—— | |
| Shares, weighted average (basic) | 56+3830%— | 1.4+211%— | 0.5r6.8−48.2%— | 0.9+373%— | 0.2r9.3−93.3%— | 2.8—— | — | — | — | — | |
| Shares, weighted average (diluted) | 56+3830%— | 1.4+211%— | 0.5r6.8−48.2%— | 0.9+371%— | 0.2r9.3−93.3%— | 2.8r14+26.3%— | 2.2+236%— | 0.7r15−95.0%— | 13+56.5%— | 8.3—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 133+1258%99.3% | 9.8−21.0%90.3% | 12+0.4%88.5% | 12+18.0%78.6% | 10+1372%83.9% | 0.7r11−86.1%23.6% | 5.1−11.6%77.7% | 5.8−13.3%75.3% | 6.7−56.1%48.1% | 15—67.2% | |
| Short-term investments | — | — | — | — | — | — | — | — | 5.00.0%36.0% | 5.0—22.1% | |
| Receivables | 0—0.0% | 0—0.0% | — | 0—0.0% | 0−100%0.0% | 0.1r0.1+180%2.0% | 0.0−92.8%0.3% | 0.3−6.0%3.8% | 0.3+2882%2.3% | 0.0—0.0% | |
| Other current assets | 0.8+24.2%0.6% | 0.7−24.9%6.2% | 0.9−61.9%6.4% | 2.4+132%14.9% | 1.0r1.9+715%8.1% | 0.1—4.1% | — | — | — | — | |
| Current assets | 134+1179%99.9% | 10−21.3%96.5% | 13−9.5%94.8% | 15+28.0%93.5% | 12r12+1184%92.0% | 0.9r13−84.1%29.7% | 5.6−13.2%85.8% | 6.5−47.7%84.7% | 12−40.4%89.7% | 21—92.5% | |
| Property, plant and equipment | 0−100%0.0% | 0.0−70.0%0.0% | 0.00.0%0.1% | 0.0+233%0.1% | 0.0−40.0%0.0% | 0.0r0.0−87.8%0.2% | 0.0−54.6%0.6% | 0.1−47.8%1.2% | 0.2−35.9%1.2% | 0.3—1.2% | |
| Right-of-use (leased) assets | 0−100%0.0% | 0.1−57.6%0.8% | 0.2−34.0%1.4% | 0.3+175%1.9% | 0.1−60.4%0.9% | 0.3+34.6%9.1% | 0.2—3.1% | — | — | — | |
| Other intangible assets | — | — | — | — | — | 0.1−78.0%4.9% | 0.7−12.4%10.2% | 0.8−13.6%9.9% | 0.9−10.8%6.4% | 1.0—4.4% | |
| Total assets | 134+1135%100% | 11−22.6%100% | 14−10.9%100% | 16+26.0%100% | 13+314%100% | 3.0r13−54.1%100% | 6.6−14.3%100% | 7.7−44.7%100% | 14−38.6%100% | 23—100% | |
| Accounts payable | 0.8−30.6%0.6% | 1.1+58.3%10.2% | 0.7−60.3%5.0% | 1.8+33.0%11.2% | 1.3−47.9%10.6% | 2.5—84.0% | — | — | — | — | |
| Debt due within a year | — | — | — | — | 0.1−91.7%0.7% | 1.0—34.7% | — | — | — | 3.7—16.4% | |
| Current liabilities | 4.6+43.3%3.5% | 3.2+25.1%29.7% | 2.6−14.1%18.4% | 3.0+20.7%19.1% | 2.5−69.1%19.9% | 8.1r3.2+560%268% | 1.2+16.5%18.6% | 1.1−30.6%13.7% | 1.5−79.3%10.9% | 7.3—32.4% | |
| Long-term debt | — | — | — | — | 0−100%0.0% | 0.1—3.1% | — | — | — | — | |
| Lease liabilities (non-current) | — | 0−100%0.0% | 0.1−57.3%0.6% | 0.2—1.3% | 0−100%0.0% | 0.1−24.6%3.7% | 0.1—2.3% | — | — | — | |
| Non-current liabilities | 0.3—0.2% | — | — | — | — | — | — | — | — | — | |
| Total liabilities | 5.0+46.5%3.7% | 3.4+23.7%31.1% | 2.7−16.6%19.5% | 3.3−36.2%20.8% | 5.1−49.1%41.1% | 10r3.3+594%335% | 1.5−10.8%22.1% | 1.6−69.6%21.3% | 5.4−52.4%38.7% | 11—49.9% | |
| Retained earnings | — | 136+11.9%1249% | 122+11.3%865% | 109+15.4%693% | 95—756% | −68r−238—−2253% | −222—−3371% | −214—−2780% | −209—−1503% | −193—−854% | |
| Shareholders' equity | 129+1627%96.3% | 7.5−33.8%68.9% | 11−9.3%80.5% | 12+69.4%79.2% | 7.4—58.9% | −17r9.8—−550% | −8.3r5.1−238%−127% | 6.0−29.0%78.7% | 8.5−24.8%61.3% | 11—50.1% | |
| Total liabilities and equity | 134+1135%100% | 11−22.6%100% | 14−10.9%100% | 16+26.0%100% | 13+314%100% | 3.0r13−54.1%100% | 6.6−14.3%100% | 7.7−44.7%100% | 14−38.6%100% | 23—100% | |
| Shares outstanding | 159+5659%— | 2.8+348%— | 0.6r9.3−79.0%— | 2.9+934%— | 0.3r14−89.7%— | 2.8r17−28.2%— | 3.9+325%— | 0.9r18−94.0%— | 15+37.4%— | 11—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | 0.0+50.0%— | 0.0−33.3%— | 0.0r0.1−97.9%22.2% | 0.1−22.6%935% | 0.2−35.8%71.5% | 0.3−14.3%111% | 0.3—2077% | |
| Share-based compensation | 4.0+507%— | 0.7+4.5%— | 0.6−39.5%250% | 1.0−45.4%— | 1.9−6.1%— | 2.0r0.6+129%14896% | 0.9+38.9%5722% | 0.6−64.2%244% | 1.8−48.6%681% | 3.4—21209% | |
| Cash from operating activities | −11—— | −12—— | −11—−4453% | −13—— | −15—— | −4.8r−9.0—−35266% | −7.3—−47133% | −7.7—−2959% | −13—−5160% | −16—−96123% | |
| Capital expenditure | — | 0—— | −0.0—−1.6% | −0.0—— | 0—— | −0.0—−44.4% | — | −0.0—−0.7% | −0.0—−4.4% | −0.1—−604% | |
| Intangible assets bought | — | — | — | — | — | — | — | — | −0.1—−31.8% | −0.1—−388% | |
| Cash from investing activities | — | 0—— | −0.0—−1.6% | −0.0—— | −0.1—— | −0.0—−44.4% | — | 5.0—1922% | −0.1−104%−36.2% | 2.4—14504% | |
| Debt repaid | — | — | — | — | — | — | — | — | −3.8—−1448% | −4.6—−28127% | |
| Shares issued | 128+1420%— | 8.4−10.4%— | 9.4−34.6%3768% | 14+176%— | 5.2+343%— | 1.2—8691% | — | — | — | — | |
| Cash from financing activities | 134+1303%— | 9.6−14.3%— | 11−26.7%4474% | 15−38.0%— | 25+1202%— | 1.9r14−71.3%13979% | 6.6+263%42806% | 1.8−63.6%698% | 5.0−79.0%1920% | 24—146120% | |
| Exchange-rate effect on cash | — | — | — | — | — | — | −0.0—−39.1% | −0.0—−3.0% | −0.0—−0.2% | −0.0—−3.3% | |
| Change in cash | 124—— | −2.6−5429%— | 0.0−97.4%19.6% | 1.9−80.7%— | 9.8—— | −2.9r5.4—−21331% | −0.7—−4367% | −0.9—−341% | −8.5−181%−3277% | 10—64498% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 0.5—100% | 0—— | 0.5—100% | 0—— | 0*—— | 0—— | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—— | 0*—— | |
| Research and development | 30+651%6035% | 12+761%— | 6.0+258%1200% | 6.0+532%— | 6.2*—— | 1.4−91.3%— | 1.7−36.3%— | 1.0−57.1%— | 0*−100%— | 16—— | 2.6—— | 2.2—— | 0.4—— | |
| General and administrative | 18+238%3616% | 5.1+235%— | 4.8+311%960% | 4.4+220%— | 3.8*+193%— | 1.5+4.9%— | 1.2−26.2%— | 1.4−6.8%— | 1.3*−16.7%— | 1.5—— | 1.6—— | 1.5—— | 1.6*—— | |
| Operating expenses | 49+324%9725% | 16+437%— | 12+329%2440% | 11+365%— | 10.0*+195%— | 2.9−18.7%— | 2.8−32.5%— | 2.3−37.1%— | 3.4*+7.2%— | 3.6—— | 4.2—— | 3.7—— | 3.2*—— | |
| Operating income | −48—−9625% | −16—— | −12—−2340% | −11—— | −10.0*—— | −2.9—— | −2.8—— | −2.3—— | −3.4*—— | −3.6—— | −4.2—— | −3.7—— | −3.2*—— | |
| Interest expense and finance costs | 0.0−72.7%0.6% | 0−100%— | 0−100%0.0% | 0.00.0%— | 0.0*−33.3%— | 0.0−16.7%— | 0.00.0%— | 0.00.0%— | 0.0*−25.0%— | 0.0—— | 0.0—— | 0.0—— | 0.0*—— | |
| Other non-operating income (expense) | 4.4+1818%886% | 1.1+1894%— | 1.1+1805%225% | 1.1+1335%— | 1.1*+2747%— | 0.1−49.1%— | 0.1−55.0%— | 0.1−45.2%— | 0.0*−79.2%— | 0.1—— | 0.1—— | 0.1—— | 0.2*—— | |
| Net income attributable to shareholders | −44—−8739% | −15—— | −11—−2115% | −9.6—— | −8.9*—— | −2.9—— | −2.8—— | −2.2—— | −3.3*—— | −3.5—— | −4.1—— | −3.5—— | −3.0*—— | |
| Earnings per share, basic | — | -0.07—— | -0.05—— | -0.05—— | — | -0.38—— | -0.58—— | -0.47—— | — | -2.32—— | -3.32—— | -4.59—— | — | |
| Earnings per share, diluted | — | -0.07—— | -0.05—— | -0.05—— | — | -0.38—— | -0.58—— | -0.47—— | — | -2.32—— | -3.32—— | -4.59—— | — | |
| Shares, weighted average (basic) | 212+2737%— | 212+2737%— | 211+4306%— | 210+4272%— | — | 7.5+398%— | 4.8+291%— | 4.8+524%— | — | 1.5—— | 1.2—— | 0.8—— | — | |
| Shares, weighted average (diluted) | 212+2737%— | 212+2737%— | 211+4306%— | 210+4272%— | — | 7.5+398%— | 4.8+291%— | 4.8+524%— | — | 1.5—— | 1.2—— | 0.8—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 114—95.8% | 114+2074%95.8% | 125+2211%98.3% | 133+1734%99.5% | 133+1258%99.3% | 5.2−35.0%75.0% | 5.4−52.3%81.3% | 7.2−35.9%88.3% | 9.8−21.0%90.3% | 8.0—86.1% | 11—88.2% | 11—89.1% | 12—88.5% | |
| Receivables | — | — | 0.5—0.4% | — | 0—0.0% | — | 0—0.0% | — | 0—0.0% | — | — | — | — | |
| Other current assets | 3.9—3.3% | 3.9+141%3.3% | 1.6+54.2%1.2% | 0.6−6.4%0.5% | 0.8+24.2%0.6% | 1.6+92.9%23.0% | 1.0+7.4%15.4% | 0.7−10.9%8.0% | 0.7−24.9%6.2% | 0.8—8.9% | 1.0—7.5% | 0.7—5.8% | 0.9—6.4% | |
| Current assets | 117—99.1% | 117+1620%99.1% | 127+1874%100.0% | 133+1589%99.9% | 134+1179%99.9% | 6.8−23.0%97.9% | 6.4−47.6%96.7% | 7.9−34.3%96.3% | 10−21.3%96.5% | 8.9—95.0% | 12—95.7% | 12—94.9% | 13—94.8% | |
| Property, plant and equipment | — | — | — | — | 0−100%0.0% | 0−100%0.0% | 0.0−75.0%0.0% | 0.0−60.0%0.0% | 0.0−70.0%0.0% | 0.0—0.0% | 0.0—0.0% | 0.0—0.0% | 0.0—0.1% | |
| Right-of-use (leased) assets | — | — | — | — | 0−100%0.0% | 0−100%0.0% | 0.0−84.5%0.3% | 0.1−68.8%0.6% | 0.1−57.6%0.8% | 0.1—1.2% | 0.1—1.1% | 0.2—1.3% | 0.2—1.4% | |
| Total assets | 119—100% | 119+1600%100% | 127+1810%100% | 133+1528%100% | 134+1135%100% | 7.0−25.3%100% | 6.7−48.2%100% | 8.2−35.3%100% | 11−22.6%100% | 9.3—100% | 13—100% | 13—100% | 14—100% | |
| Accounts payable | 1.4—1.2% | 1.4+1.3%1.2% | 1.8+33.6%1.4% | 2.7+262%2.0% | 0.8−30.6%0.6% | 1.4+290%20.5% | 1.4+167%20.6% | 0.7+62.3%9.1% | 1.1+58.3%10.2% | 0.4—3.9% | 0.5—4.0% | 0.5—3.6% | 0.7—5.0% | |
| Current liabilities | 5.8—4.9% | 5.8+67.5%4.9% | 5.2+32.1%4.1% | 5.6+102%4.2% | 4.6+43.3%3.5% | 3.5+29.7%49.9% | 4.0+40.0%59.5% | 2.8+12.6%33.9% | 3.2+25.1%29.7% | 2.7—28.7% | 2.8—22.0% | 2.5—19.5% | 2.6—18.4% | |
| Lease liabilities (non-current) | — | — | — | — | — | — | — | — | 0−100%0.0% | 0—0.0% | 0.0—0.2% | 0.1—0.5% | 0.1—0.6% | |
| Non-current liabilities | 0.3—0.2% | 0.3—0.2% | — | — | 0.3—0.2% | — | — | — | — | — | — | — | — | |
| Total liabilities | 6.1—5.1% | 6.1+62.3%5.1% | 5.6+37.6%4.4% | 6.0+108%4.5% | 5.0+46.5%3.7% | 3.8+37.9%53.9% | 4.0+38.5%60.7% | 2.9+10.5%34.9% | 3.4+23.7%31.1% | 2.7—29.2% | 2.9—22.7% | 2.6—20.5% | 2.7—19.5% | |
| Retained earnings | — | — | — | — | — | — | 141—2115% | 138—1687% | 136+11.9%1249% | 133—1420% | −129—−1003% | −125—−988% | 122—865% | |
| Shareholders' equity | 112—94.9% | 112+3401%94.9% | 122+4547%95.6% | 127+2289%95.5% | 129+1627%96.3% | 3.2−51.4%46.1% | 2.6−73.7%39.3% | 5.3−47.0%65.1% | 7.5−33.8%68.9% | 6.6—70.8% | 9.9—77.3% | 10—79.5% | 11—80.5% | |
| Total liabilities and equity | 119—100% | 119+1600%100% | 127+1810%100% | 133+1528%100% | 134+1135%100% | 7.0−25.3%100% | 6.7−48.2%100% | 8.2−35.3%100% | 11−22.6%100% | 9.3—100% | 13—100% | 13—100% | 14—100% | |
| Shares outstanding | 174—— | 174+1813%— | 174+3516%— | 167+3708%— | 159+5659%— | 9.1+661%— | 4.8+397%— | 4.4+416%— | 2.8+348%— | 1.2—— | 1.0—— | 0.9—— | 0.6r9.3—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 18+6034%3570% | 5.1+5842%— | 4.8+7858%955% | 4.3+6128%— | 3.7*+4740%— | 0.1−7.6%— | 0.1−83.2%— | 0.1−41.5%— | 0.1*−58.4%— | 0.1r0.1—— | 0.4—— | 0.1—— | 0.2*—— | |
| Cash from operating activities | −26—−5279% | −12*—— | −7.6*—−1521% | −3.9—— | −3.1*—— | −3.6*—— | −1.8*—— | −2.3—— | −2.4*—— | −3.1*—— | −3.5*—— | −3.2—— | −2.7*—— | |
| Capital expenditure | — | — | — | — | — | — | — | — | 0*—— | 0*—— | — | — | 0*—— | |
| Cash from investing activities | — | — | — | — | — | — | — | — | 0*—— | 0*—— | — | — | 0*—— | |
| Shares issued | 132+2869%26334% | 0.2*—— | 0*—0.0% | 3.3—— | 128*+2791%— | 0*—— | 0*−100%— | 0—— | 4.4*—— | 0*—— | 4.0*—— | 0—— | 0*—— | |
| Cash from financing activities | 135+1754%26962% | 0.2*−94.1%— | 0.1*+3575%29.4% | 3.1—— | 131*+3055%— | 3.4*—— | 0.0*−99.9%— | −0.3−113%— | 4.2*—— | −0.2*—— | 3.6*—— | 2.0—— | −0.1*—— | |
| Change in cash | 108—21683% | −12*—— | −7.5*—−1491% | −0.8—— | 128*+7097%— | −0.2*—— | −1.8*−2455%— | −2.6—— | 1.8*—— | −3.3*—— | 0.1*—— | −1.2—— | −2.9*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Palisade Bio, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025J.D. Finley | $18.8 M | $22.7 M | — | $3 |
| 2024J.D. Finley | $813 K | $692 K | — | $2 |
| 2023J.D. Finley | $1.3 M | $1.0 M | — | $11 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Palisade Bio, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Directors and officers 5 · Material agreement 3 · Unregistered share sale 2 · Bylaws or fiscal year changed 2 · Shareholder vote 4 · Results announced 3
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officersMaterial agreement | 8-K | |
| Shareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2024 | $4 M | Private placement after listing | $2 to $10 million | 1 | equity, options | SEC |
| Feb 2024 | $3 M | Private placement after listing | $2 to $10 million | 15 | options | SEC |
| Apr 2023 | $4 M | Private placement after listing | $2 to $10 million | 9 | equity, options | SEC |
| Jan 2023 | $3 M | Private placement after listing | $2 to $10 million | 6 | options | SEC |
| May 2022 | $2 M | Private placement after listing | $2 to $10 million | 5 | options | SEC |
| Jan 2020 | $8 M | Private placement after listing | $2 to $10 million | 3 | options | SEC |
| Dec 2016 | $20 M | Private placement after listing | $10 to $50 million | 1 | equity | SEC |
| May 2016 | $1 M | Private placement after listing | Under $2 million | 3 | equity, options | SEC |
| Oct 2014 | $10 M | Private placement after listing | $10 to $50 million | 1 | debt, options | SEC |
| Mar 2013 | $2 M | Private placement after listing | Under $2 million | 3 | equity, debt, options | SEC |
| Dec 2009 | $2 M | No. 1 | Under $2 million | 1 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2016 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Palisade Bio, Inc. compares in Biotechnology
- Market cap$215 M · higher than 45% of 726
- Revenue$0 M · higher than 0% of 647
- Price / book1.7× · lower than 63% of 534
- FCF yield-5.7% · higher than 69% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Palisade Bio, Inc.🇺🇸 | $215 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 28, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 18, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, value.today research, SEC filing, SEC annual report, GLEIF register.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Palisade Bio, Inc.? Verify and update this profile — free
Show Palisade Bio, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.